UB Paderborn / Katalog / Suche / in CDI

A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy

Journal of pharmacokinetics and pharmacodynamics, 2021-08, Vol.48 (4), p.465-477

2021

Volltextzugriff (PDF)

Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development

CPT: pharmacometrics and systems pharmacology, 2024-07, Vol.13 (7), p.1170-1179

2024

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK‐448, for its anti‐tumor efficacy in a rat xenograft model

Biopharmaceutics & drug disposition, 2020-07, Vol.41 (7), p.283-294

2020

Volltextzugriff (PDF)

Pharmacokinetics of Recombinant Human Antithrombin in Delivery and Surgery Patients With Hereditary Antithrombin Deficiency

Clinical and applied thrombosis/hemostasis, 2014-05, Vol.20 (4), p.355-364

2014

Volltextzugriff (PDF)

Pharmacokinetics of Clindamycin in Pregnant Women in the Peripartum Period

Antimicrobial Agents and Chemotherapy, 2010-05, Vol.54 (5), p.2175-2181

2010

Volltextzugriff (PDF)

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus

Journal of pharmacokinetics and pharmacodynamics, 2006-06, Vol.33 (3), p.313-343

2006

Volltextzugriff (PDF)

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design

Pharmaceutical research, 2009-10, Vol.26 (10), p.2259-2269

2009

Volltextzugriff (PDF)

Pharmacokinetics of Amoxicillin in Maternal, Umbilical Cord, and Neonatal Sera

Antimicrobial Agents and Chemotherapy, 2009-04, Vol.53 (4), p.1574-1580

2009

Volltextzugriff (PDF)

Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks

Antimicrobial Agents and Chemotherapy, 2007-10, Vol.51 (10), p.3720-3725

2007

Volltextzugriff (PDF)

Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes

American journal of obstetrics and gynecology, 2008, Vol.198 (1), p.108.e1-108.e6

2008

Volltextzugriff (PDF)

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar

Journal of clinical pharmacology, 2014-04, Vol.54 (4), p.453-461

2014

Volltextzugriff (PDF)

Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years

Clinical pharmacokinetics, 2009-01, Vol.48 (6), p.371-385

2009

Volltextzugriff (PDF)

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes

Diabetes technology & therapeutics, 2015-03, Vol.17 (3), p.215

2015

Volltextzugriff (PDF)

Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children

Clinical pharmacokinetics, 2011, Vol.50 (1), p.51-63

2011

Volltextzugriff (PDF)

Disease system analysis: basic disease progression models in degenerative disease

Pharmaceutical research, 2005-07, Vol.22 (7), p.1038-1049

2005

Volltextzugriff (PDF)

Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar

Journal of clinical pharmacology, 2013-03, Vol.53 (3), p.256-263

2013

Volltextzugriff (PDF)

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation

Biopharmaceutics & drug disposition, 2017-12, Vol.38 (9), p.543-552

2017

Volltextzugriff (PDF)

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK‐357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation

Biopharmaceutics & drug disposition, 2017-09, Vol.38 (6), p.373-380

2017

Volltextzugriff (PDF)

Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain

The Journal of pharmacology and experimental therapeutics, 2010-08, Vol.334 (2), p.599

2010

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery

Anesthesiology (Philadelphia), 2006-12, Vol.105 (6), p.1135-1146

2006

Volltextzugriff (PDF)

Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery

Anesthesiology (Philadelphia), 2006-03, Vol.104 (3), p.466-474

2006

Volltextzugriff (PDF)

Mechanistic Disease Progression Analysis Indicates That Pioglitazone Improves Beta-Cell Function in Treatment-Naïve Type 2 Diabetics

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A65

2005

Volltextzugriff (PDF)

Treatment Efficacy of Pioglitazone in Combination Therapy on Disease Progression in Type 2 Diabetes Mellitus over a Two-Year Period

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A4

2005

Volltextzugriff (PDF)

Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: A comparison between propofol 6% and propofol 1

Clinical pharmacology and therapeutics, 2002-12, Vol.72 (6), p.670-684

2002

Volltextzugriff (PDF)

A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling

Pharmaceutical research, 2000-12, Vol.17 (12), p.1516-1525

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy

Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development

Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK‐448, for its anti‐tumor efficacy in a rat xenograft model

Pharmacokinetics of Recombinant Human Antithrombin in Delivery and Surgery Patients With Hereditary Antithrombin Deficiency

Pharmacokinetics of Clindamycin in Pregnant Women in the Peripartum Period

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus

Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design

Pharmacokinetics of Amoxicillin in Maternal, Umbilical Cord, and Neonatal Sera

Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks

Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar

Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes

Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children

Disease system analysis: basic disease progression models in degenerative disease

Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK‐357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation

Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain

Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery

Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery

Mechanistic Disease Progression Analysis Indicates That Pioglitazone Improves Beta-Cell Function in Treatment-Naïve Type 2 Diabetics

Treatment Efficacy of Pioglitazone in Combination Therapy on Disease Progression in Type 2 Diabetes Mellitus over a Two-Year Period

Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: A comparison between propofol 6% and propofol 1

A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling

Suchergebnisse filtern